Dietary glycemic load and cancer recurrence and survival in patients with stage III colon cancer: findings from CALGB 89803 - PubMed (original) (raw)
. 2012 Nov 21;104(22):1702-11.
doi: 10.1093/jnci/djs399. Epub 2012 Nov 7.
Kaori Sato, Donna Niedzwiecki, Cynthia Ye, Leonard B Saltz, Robert J Mayer, Rex B Mowat, Renaud Whittom, Alexander Hantel, Al Benson, Devin S Wigler, Alan Venook, Charles S Fuchs
Affiliations
- PMID: 23136358
- PMCID: PMC3502194
- DOI: 10.1093/jnci/djs399
Dietary glycemic load and cancer recurrence and survival in patients with stage III colon cancer: findings from CALGB 89803
Jeffrey A Meyerhardt et al. J Natl Cancer Inst. 2012.
Abstract
Background: The influence of glycemic load and related measures on survival among colon cancer patients remains largely unknown.
Methods: We conducted a prospective, observational study of 1011 stage III colon cancer patients reporting dietary intake during and 6 months after participation in an adjuvant chemotherapy trial. We examined the influence of glycemic load, glycemic index, fructose, and carbohydrate intakes on cancer recurrence and mortality using Cox proportional hazards regression; all tests of statistical significance were two-sided.
Results: Stage III colon cancer patients in the highest quintile of dietary glycemic load experienced an adjusted hazard ratio (HR) for disease-free survival of 1.79 (95% confidence interval [CI] = 1.29 to 2.48), compared with those in the lowest quintile (P (trend) across quintiles <.001). Increased glycemic load was associated with similar detriments in recurrence-free (P (trend) across quintiles <.001) and overall survival (P (trend) across quintiles <.001). These associations differed statistically significant by body mass index (BMI) (P (interaction) =.01). Whereas glycemic load was not associated with disease-free survival in patients with BMI < 25kg/m(2), higher glycemic load was statistically significant associated with worse disease-free survival among overweight or obese participants (BMI ≥ 25kg/m(2); HR = 2.26; 95% CI = 1.53 to 3.32; P (trend) across quintiles <.001). Increasing total carbohydrate intake was similarly associated with inferior disease-free, recurrence-free, and overall survival (P (trend) across quintiles <.001).
Conclusion: Higher dietary glycemic load and total carbohydrate intake were statistically significant associated with an increased risk of recurrence and mortality in stage III colon cancer patients. These findings support the role of energy balance factors in colon cancer progression and may offer potential opportunities to improve patient survival.
Figures
Figure 1.
Derivation of cohort. Q1 = questionnaire 1 (midway through adjuvant therapy); Q2 = questionnaire 2 (6 months after completion of adjuvant therapy). Caloric intake exclusion = Less than 600 calories or greater than 4200 calories per day for men and less than 500 calories or greater than 3500 calories per day for women.
Figure 2.
Hazard ratio (HR) for disease-free survival according to combinations of the dietary glycemic load by quintile and median levels of Western pattern diet.
Comment in
- Colon cancer recurrence: insights from the interface between epidemiology, laboratory science, and clinical medicine.
Meropol NJ, Berger NA. Meropol NJ, et al. J Natl Cancer Inst. 2012 Nov 21;104(22):1697-8. doi: 10.1093/jnci/djs454. Epub 2012 Nov 7. J Natl Cancer Inst. 2012. PMID: 23136359 Free PMC article. No abstract available.
Similar articles
- Dietary Insulin Load and Cancer Recurrence and Survival in Patients With Stage III Colon Cancer: Findings From CALGB 89803 (Alliance).
Morales-Oyarvide V, Yuan C, Babic A, Zhang S, Niedzwiecki D, Brand-Miller JC, Sampson-Kent L, Ye X, Li Y, Saltz LB, Mayer RJ, Mowat RB, Whittom R, Hantel A, Benson A, Atienza D, Messino M, Kindler H, Venook A, Ogino S, Wu K, Willett WC, Giovannucci EL, Wolpin BM, Meyerhardt JA, Fuchs CS, Ng K. Morales-Oyarvide V, et al. J Natl Cancer Inst. 2019 Feb 1;111(2):170-179. doi: 10.1093/jnci/djy098. J Natl Cancer Inst. 2019. PMID: 30726946 Free PMC article. Clinical Trial. - Associations of artificially sweetened beverage intake with disease recurrence and mortality in stage III colon cancer: Results from CALGB 89803 (Alliance).
Guercio BJ, Zhang S, Niedzwiecki D, Li Y, Babic A, Morales-Oyarvide V, Saltz LB, Mayer RJ, Mowat RB, Whittom R, Hantel A, Benson A, Atienza D, Messino M, Kindler H, Venook A, Ogino S, Zoltick ES, Stampfer M, Ng K, Wu K, Willett WC, Giovannucci EL, Meyerhardt JA, Fuchs CS. Guercio BJ, et al. PLoS One. 2018 Jul 19;13(7):e0199244. doi: 10.1371/journal.pone.0199244. eCollection 2018. PLoS One. 2018. PMID: 30024889 Free PMC article. - Association of dietary patterns with cancer recurrence and survival in patients with stage III colon cancer.
Meyerhardt JA, Niedzwiecki D, Hollis D, Saltz LB, Hu FB, Mayer RJ, Nelson H, Whittom R, Hantel A, Thomas J, Fuchs CS. Meyerhardt JA, et al. JAMA. 2007 Aug 15;298(7):754-64. doi: 10.1001/jama.298.7.754. JAMA. 2007. PMID: 17699009 - Added sugar, glycemic index and load in colon cancer risk.
Galeone C, Pelucchi C, La Vecchia C. Galeone C, et al. Curr Opin Clin Nutr Metab Care. 2012 Jul;15(4):368-73. doi: 10.1097/MCO.0b013e3283539f81. Curr Opin Clin Nutr Metab Care. 2012. PMID: 22510682 Review. - Carbohydrates, glycemic index, glycemic load, and breast cancer risk: a systematic review and dose-response meta-analysis of prospective studies.
Schlesinger S, Chan DSM, Vingeliene S, Vieira AR, Abar L, Polemiti E, Stevens CAT, Greenwood DC, Aune D, Norat T. Schlesinger S, et al. Nutr Rev. 2017 Jun 1;75(6):420-441. doi: 10.1093/nutrit/nux010. Nutr Rev. 2017. PMID: 28969357 Review.
Cited by
- SEOM-GEMCAD-TTD clinical guidelines for the adjuvant treatment of colon cancer (2023).
Pericay C, Montagut C, Reina JJ, Melian M, Alcaide J, Tarazona N, Ruiz-Casado A, González-Flores E, Graña B, Grávalos C. Pericay C, et al. Clin Transl Oncol. 2024 Nov;26(11):2812-2825. doi: 10.1007/s12094-024-03559-5. Epub 2024 Jun 24. Clin Transl Oncol. 2024. PMID: 38914755 Free PMC article. - Lifestyle Factors and Cancer: A Narrative Review.
Sharman R, Harris Z, Ernst B, Mussallem D, Larsen A, Gowin K. Sharman R, et al. Mayo Clin Proc Innov Qual Outcomes. 2024 Mar 4;8(2):166-183. doi: 10.1016/j.mayocpiqo.2024.01.004. eCollection 2024 Apr. Mayo Clin Proc Innov Qual Outcomes. 2024. PMID: 38468817 Free PMC article. - Tumour response following preoperative chemotherapy is affected by body mass index in patients with colorectal liver metastases.
Song HC, Zhou HC, Gu P, Bao B, Sun Q, Mei TM, Cui W, Yao K, Yao HZ, Zhang SY, Wang YS, Song RP, Wang JZ. Song HC, et al. World J Gastrointest Oncol. 2024 Feb 15;16(2):331-342. doi: 10.4251/wjgo.v16.i2.331. World J Gastrointest Oncol. 2024. PMID: 38425385 Free PMC article. - Variety of Fruit and Vegetables and Alcohol Intake are Associated with Gut Microbial Species and Gene Abundance in Colorectal Cancer Survivors.
Kyaw TS, Upadhyay V, Tolstykh I, Van Loon K, Laffan A, Stanfield D, Gempis D, Kenfield SA, Chan JM, Piawah S, Atreya CE, Ng K, Venook A, Kidder W, Turnbaugh PJ, Van Blarigan EL. Kyaw TS, et al. Am J Clin Nutr. 2023 Sep;118(3):518-529. doi: 10.1016/j.ajcnut.2023.07.011. Epub 2023 Jul 18. Am J Clin Nutr. 2023. PMID: 37474105 Free PMC article.
References
- Giovannucci E. Insulin, insulin-like growth factors and colon cancer: a review of the evidence J Nutr 2001. 131(11)(suppl):3109S–3120S - PubMed
- Kaaks R, Lukanova A. Energy balance and cancer: the role of insulin and insulin-like growth factor-I Proc Nutr Soc. 2001. 60(1):91–106 - PubMed
- Giovannucci E. Diet, body weight, and colorectal cancer: a summary of the epidemiologic evidence J Womens Health (Larchmt). 2003. 12(2):173–182 - PubMed
- Moghaddam AA, Woodward M, Huxley R. Obesity and risk of colorectal cancer: a meta-analysis of 31 studies with 70,000 events Cancer Epidemiol Biomarkers Prev. 2007. 16(12):2533–2547 - PubMed
- Samad AK, Taylor RS, Marshall T, et al. A meta-analysis of the association of physical activity with reduced risk of colorectal cancer Colorectal Dis. 2005. 7(3):204–13 - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- CA33601/CA/NCI NIH HHS/United States
- UL1 TR000150/TR/NCATS NIH HHS/United States
- R01 CA149222/CA/NCI NIH HHS/United States
- CA 118553/CA/NCI NIH HHS/United States
- P50CA127003/CA/NCI NIH HHS/United States
- CA31946/CA/NCI NIH HHS/United States
- CA149222/CA/NCI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Medical